Parallel Trade Adds Up As Abacus Prepares IPO
Executive Summary
With revenues from its parallel trade business climbing 50% year-on-year since 2015, Denmark's Abacus is to seek a listing in Germany to help it keep up with demand.
You may also be interested in...
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
‘No-Deal’ Brexit: UK Would Keep Rules on Patents, SPCs & Parallel Trade
The latest “technical notices” from the government say that there will be no material change to the rules on intellectual property protections and compulsory licensing if the UK leaves the EU without a deal, and that the government also intends to continue allowing parallel imports of medicines from Europe to the UK.
Updated EU Guide On Safety Features Addresses Parallel Trade Repackaging
The EU guideline on complying with the requirement to affix safety features on medicine packs has been updated to address specific aspects of parallel trade, such as re-sealing of medicine packs that are legally opened to replace patient information leaflets.